Predicting Tamoxifen's Effectiveness: Testing for CYP2D6 Gains More Steam
Discussed in this blog two years ago, many academicians now recommend testing for CYP2D6 metabolic signature to determine if postmenopausal women should switch from tamoxifen to aromatase inhibitors. However, given that most oncologists offer aromatase inhibitors preferentially to postmenopausal women over tamoxifen the question is still... Read more
